Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Fennec Pharmaceuticals (FENC) Equity Ratio (2016 - 2025)

Fennec Pharmaceuticals filings provide 16 years of Equity Ratio readings, the most recent being 0.5 for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 484.85% to 0.5 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.5, a 484.85% increase, with the full-year FY2025 number at 0.5, up 484.85% from a year prior.
  • Equity Ratio hit 0.5 in Q4 2025 for Fennec Pharmaceuticals, up from 0.09 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.9 in Q1 2021 to a low of 0.53 in Q3 2023.
  • Median Equity Ratio over the past 5 years was 0.05 (2024), compared with a mean of 0.12.
  • The widest YoY moves for Equity Ratio: up 484.85% in 2025, down 674.05% in 2025.
  • Fennec Pharmaceuticals' Equity Ratio stood at 0.7 in 2021, then tumbled by 113.55% to 0.1 in 2022, then tumbled by 353.66% to 0.43 in 2023, then surged by 69.8% to 0.13 in 2024, then skyrocketed by 484.85% to 0.5 in 2025.
  • The last three reported values for Equity Ratio were 0.5 (Q4 2025), 0.09 (Q3 2025), and 0.17 (Q2 2025) per Business Quant data.